

REVIEW

Open Access

# Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature

Indraneel Datta<sup>1</sup>, Chad G Ball<sup>1\*</sup>, Lucas Rudmik<sup>1</sup>, S Morad Hameed<sup>2</sup>, John B Kortbeek<sup>1</sup>

## Abstract

Deep venous thrombosis prophylaxis is essential to the appropriate management of multisystem trauma patients. Without thromboprophylaxis, the rate of venous thrombosis and subsequent pulmonary embolism is substantial. Three prophylactic modalities are common: pharmacologic anticoagulation, mechanical compression devices, and inferior vena cava filtration. A systematic review was completed using PRISMA guidelines to evaluate the potential complications of DVT prophylactic options. Level one evidence currently supports the use of low molecular weight heparins for thromboprophylaxis in the trauma patient. Unfortunately, multiple techniques are not infrequently required for complex multisystem trauma patients. Each modality has potential complications. The risks of heparin include bleeding and heparin induced thrombocytopenia. Mechanical compression devices can result in local soft tissue injury, bleeding and patient non-compliance. Inferior vena cava filters migrate, cause inferior vena cava occlusion, and penetrate the vessel wall. While the use of these techniques can be life saving, they must be appropriately utilized.

## Introduction

Multisystem traumatic injury is a significant risk factor for the development of a deep venous thrombosis (DVT). Without thromboprophylaxis, overall DVT rates exceed 50% [1-3]. Although DVT alone is not life-threatening, a resulting pulmonary embolism (PE) carries potentially significant morbidity and mortality. PE is estimated to be the third leading cause of death in injured patients who survive beyond the first day of admission [2,4-6]. Trauma patients at the highest risk have been identified as those with a lower extremity or pelvic fracture, spinal cord injury, brain injury (Glasgow Coma Score < 8), increased age, surgical intervention, femoral central venous catheter, and prolonged immobilization [2,3,7-9].

Modalities available for trauma patient thromboprophylaxis are classified into pharmacologic anticoagulation, mechanical compression devices, and inferior vena cava (IVC) filtration. Although the options are numerous, level one evidence currently supports the use of pharmacologic anticoagulation with low molecular

weight heparins (LMWHs) as the primary DVT prophylactic agent [10]. Other modalities such as mechanical compression devices and IVC filters are not used for primary thromboprophylaxis, but may be helpful when LMWHs are contraindicated. This systematic review describes the potential complications associated with LMWHs, mechanical compression devices, and IVC filters.

## Methods

All scientific publications discussing the use of biochemical, mechanical, and IVC filter prophylaxis for the prevention of DVT after trauma were identified using PubMed, EMBASE, and Medline. Search terms included: "DVT", "deep venous thrombosis", "complications", "trauma", "injury", "DVT prophylaxis", "low molecular weight heparin", "heparin", "chemical", "mechanical", "IVC filter" and/or "heparin-induced thrombocytopenia." The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) was employed. Only English language publications were included. Once identified, manuscripts were reviewed for relevance to the topic of DVT prophylaxis, and sorted according to their prophylactic mode of choice. This review included all

\* Correspondence: ball.chad@gmail.com

<sup>1</sup>Department of Surgery, University of Calgary, Calgary, Canada

mas. This was the only study to experience insertion related complications, however all filters were placed at the bedside under ultrasound guidance.

There is poor long-term follow-up data for trauma patients with retrievable filters that were not removed. In studies involving non-trauma patients with permanent retrievable filters, filter migration occurred between 3% and 8%, and IVC occlusion rates were reported between 4% and 15% [72-75,77,78]. Of the four studies analyzing retrievable filters in injured patients, none reported filter migration or IVC occlusion rates. One patient did have a symptomatic IVC penetration for a calculated rate of 0.4% however.

Failed filter retrieval does not carry an immediate complication to the patient, but it does expose the patient to the long-term complications of a permanent filter. Failed retrieval rates in trauma patients are reported between 0% and 4% with a calculated rate of 2.8% (Table 6).

## Conclusion

Pharmacologic anticoagulation using LMWHs is the recommended primary thromboprophylaxis modality in trauma patients. In this review we calculated the risk of bleeding and HIT to be 3.9% and 0.7% respectively. These values are slightly higher than the previously published rates of 3.1% and 0.4% [9]. Mechanical compression device thromboprophylaxis should not be used as an initial choice, however evidence supports its role in trauma patients when LMWHs are contraindicated. Mechanical devices have a generally safe profile, however they must be used with caution in patients with peripheral vascular disease and peripheral neuropathy for risks of soft tissue injury and ulceration. Although the mechanism that predisposes patients to bleeding while using mechanical devices is unclear, the calculated risk of bleeding is 2.6%. This may reflect the general risk of bleeding in a trauma patient. Patient compliance is poor but may be improved with adequate patient and staff education regarding the benefits of mechanical thromboprophylaxis. When LMWH and mechanical device thromboprophylaxis are contraindicated, retrievable IVC filters should be considered in high-risk trauma patients [79]. Current high risk features include: spinal cord injury with paraplegia or tetraplegia, severe brain injury (Glasgow Coma Score <8), multiple long bone fractures and complex pelvic fractures [8]. Future studies are needed to identify the trauma populations that will benefit from prophylactic IVC filtration. Retrievable IVC filters have the benefit of providing protection from PE in the early, high-risk period while consequently being removed to prevent the long-term complications of permanent IVC filtration. Although retrievable filters are removed in the majority of patients, they may also be left in place for permanent filtration if necessary. The

versatility of the retrievable filter has virtually eliminated the use of permanent filters. Long-term follow-up studies of permanent IVC filtration using retrievable filters are required. The risk of insertion related complications, such as arterial puncture, hematoma, infection, and pneumothorax is calculated to be 2.6%. There were no reported filter migration or IVC occlusion events in the short-term. Although a failed retrieval is not a direct complication, it results in permanent IVC filtration and places the patient at risk for future complications. The failed retrieval rate is calculated to be 2.8%. While the essential nature of thromboprophylaxis in the management of multi-system trauma patients can not be understated, understanding their potential complications is an absolute requirement for both patient counselling and clinical care.

## Author details

<sup>1</sup>Department of Surgery, University of Calgary, Calgary, Canada. <sup>2</sup>Department of Surgery, University of British Columbia, Vancouver, Canada.

## Authors' contributions

ID - Study design, data analysis, manuscript writing & editing.  
CGB - Data analysis, manuscript writing & editing.  
LRR - Data analysis & manuscript writing.  
SMH - Data analysis, manuscript writing & editing.  
JBK - Study design, data analysis, manuscript writing & editing.  
All authors read and approved the final manuscript.

## Competing interests

The authors declare that they have no competing interests.

Received: 2 June 2009

Accepted: 6 January 2010 Published: 6 January 2010

## References

1. Kudsk KA, Fabian TC, Baum S, Gold RE, Mangiante E, Voeller G: **Silent deep vein thrombosis in immobilized multiple trauma patients.** *Am J Surg* 1989, **158**:515-9.
2. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP: **A prospective study of venous thromboembolism after major trauma.** *N Engl J Med* 1994, **331**:1601-6.
3. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, Wheeler HB: **Prevention of venous thromboembolism.** *Chest* 2001, **119**(1 Suppl):132S-75S.
4. Acosta JA, Yang JC, Winchell RJ, Simons RK, Fortlage DA, Hollingsworth-Fridlund P, Hoyt DB: **Lethal injuries and time to death in a level I trauma center.** *J Am Coll Surg* 1998, **186**:528-33.
5. O'Malley KF, Ross SE: **Pulmonary embolism in major trauma patients.** *J Trauma* 1990, **30**:748-50.
6. Rogers FB, Shackford SR, Wilson J, Ricci MA, Morris CS: **Prophylactic vena cava filter insertion in severely injured trauma patients: indications and preliminary results.** *J Trauma* 1993, **35**:637-42.
7. Meissner MH, Chandler WL, Elliott JS: **Venous thromboembolism in trauma: a local manifestation of systemic hypercoagulability?.** *J Trauma* 2003, **54**:224-31.
8. Rogers FB, Cipolle MD, Velmahos G, Rozycki G, Luchette FA: **Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines work group.** *J Trauma* 2002, **53**:142-64.
9. Velmahos GC, Kern J, Chan LS, Odor D, Murray JA, Shekelle P: **Prevention of venous thromboembolism after injury: an evidence-based report-part II: analysis of risk factors and evaluation of the role of vena caval filters.** *J Trauma* 2000, **49**:140-4.

10. Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamilton PA: **A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma.** *N Engl J Med* 1996, **335**:701-7.
11. Weitz JI: **Low-molecular-weight heparins.** *N Engl J Med* 1997, **337**:688-98.
12. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG: **Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.** *Chest* 2004, **126**(3 Suppl):338S-400S.
13. Kurtoglu M, Yanar H, Bilsel Y, Guloglu R, Kizilirmak S, Buyukurt D, Granit V: **Venous thromboembolism prophylaxis after head and spinal trauma: intermittent pneumatic compression devices versus low molecular weight heparin.** *World J Surg* 2004, **28**:807-11.
14. Norwood SH, McAuley CE, Berne JD, Vallina VL, Kerns DB, Grahm TW, Short K, McLarty JW: **Prospective evaluation of the safety of enoxaparin prophylaxis for venous thromboembolism in patients with intracranial hemorrhagic injuries.** *Arch Surg* 2002, **137**:696-702.
15. Cothren CC, Smith WR, Moore EE, Morgan SH: **Utility of once-daily dose of low-molecular-weight heparin to prevent venous thromboembolism in intermsystem trauma patients.** *World J Surg* 2007, **31**:98-104.
16. Muntz J, Scott DA, Lloyd A, Egger M: **Major bleeding rates after prophylaxis against venous thromboembolism: systematic review, meta-analysis, and cost implications.** *Int J Technol Assess Health Care* 2004, **20**:405-14.
17. Green D, Lee MY, Lim AC, Chmiel JS, Vetter M, Pang T, Chen D, Fenton L, Yarkony GM, Meyer PR Jr: **Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin.** *Ann Intern Med* 1990, **113**:571-4.
18. Spinal Cord Injury Thromboprophylaxis Investigators: **Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin.** *J Trauma* 2003, **54**:1116-26.
19. Ginzburg E, Cohn SM, Lopez J, Jackowski J, Brown J, Brown M, Hameed SM, Miami Deep Vein Thrombosis Study Group: **Randomized clinical trial of intermittent pneumatic compression and low molecular weight heparin in trauma.** *Br J Surg* 2003, **90**:1338-44.
20. Knudson MM, Morabito D, Paiement GD, Shackelford S: **Use of low molecular weight heparin in preventing thromboembolism in trauma patients.** *J Trauma* 1996, **41**:446-59.
21. Lindhoff-Last E, Nakov R, Misselwitz F, Breddin HK, Bauersachs R: **Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin.** *Br J Haematol* 2002, **118**:1137-42.
22. Amiral J, Bridey F, Wolf M, Boyer-Neumann C, Fressinaud E, Vissac AM, Peunaud-Debayle E, Dreyfus M, Meyer D: **Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases.** *Thromb Haemost* 1995, **73**:21-8.
23. Amiral J, Wolf M, Fischer A, Boyer-Neumann C, Vissac A, Meyer D: **Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia.** *Br J Haematol* 1996, **92**:954-9.
24. Warkentin TE, Roberts RS, Hirsh J, Kelton JG: **An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients.** *Arch Intern Med* 2003, **163**:2518-24.
25. Bauer TL, Arepally G, Konkole BA, Mestichelli B, Shapiro SS, Cines DB, Poncz M, McNulty S, Amiral J, Hauck WW, Edie RN, Mannion JD: **Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery.** *Circulation* 1997, **95**:1242-6.
26. Lindhoff-Last E, Eichler P, Stein M, Plagemann J, Gerdson F, Wagner R, Ehrly AM, Bauersachs R: **A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery.** *Thromb Res* 2000, **97**:387-93.
27. Visentin GP, Malik M, Cyganiak KA, Aster RH: **Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes.** *J Lab Clin Med* 1996, **128**:376-83.
28. Warkentin TE, Sheppard JA, Horsewood P, Simposin PJ, Moore JC, Kelton JG: **Impact of the patient population on the risk for heparin-induced thrombocytopenia.** *Blood* 2000, **96**:1703-8.
29. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: **Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.** *N Engl J Med* 1995, **332**:1330-5.
30. Lubenow N, Hinz P, Ekkernkamp A, Greinacher A: **Should patients be informed about the risk of heparin-induced thrombocytopenia before prolonged low-molecular-weight heparin thromboprophylaxis post-trauma/orthopedic surgery?** *Eur J Haematol* 2007, **79**:187-90.
31. Haentjens P: **Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium).** *Injury* 1996, **27**:385-90.
32. Schwarcz TH, Quick RC, Minion DJ, Kearney PA, Kwolok CJ, Endean ED: **Enoxaparin treatment in high-risk trauma patients limits the utility of surveillance venous duplex scanning.** *J Vasc Surg* 2001, **34**:447-52.
33. Agu O, Hamilton G, Baker D: **Graduated compression stockings in the prevention of venous thromboembolism.** *Br J Surg* 1999, **86**:992-1004.
34. Morris RJ, Woodcock JP: **Evidence-based compression: prevention of stasis and deep vein thrombosis.** *Ann Surg* 2004, **239**:162-71.
35. Elliott CG, Dudley TM, Egger M, Orme JF, Clemmer TP, Horn SD, Weaver L, Handrahan D, Thomas F, Merrell S, Kitterman N, Yeates S: **Calf-thigh sequential pneumatic compression compared with plantar venous pneumatic compression to prevent deep-vein thrombosis after non-lower extremity trauma.** *J Trauma* 1999, **47**:25-32.
36. Lachmann EA, Rook JL, Tunkel R, Nagler W: **Complications associated with intermittent pneumatic compression.** *Arch Phys Med Rehabil* 1992, **73**:482-5.
37. McGrory BJ, Burke DW: **Peroneal nerve palsy following intermittent sequential pneumatic compression.** *Orthopedics* 2000, **23**:1103-5.
38. Pittman GR: **Peroneal nerve palsy following sequential pneumatic compression.** *Jama* 1989, **261**:2201-2.
39. Cohen SA, Hurt WG: **Compartment syndrome associated with lithotomy position and intermittent compression stockings.** *Obstet Gynecol* 2001, **97**:832-3.
40. Verdolin MH, Toth AS, Schroeder R: **Bilateral lower extremity compartment syndromes following prolonged surgery in the low lithotomy position with serial compression stockings.** *Anesthesiology* 2000, **92**:1189-91.
41. Comerota AJ, Katz ML, White JV: **Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail?** *Am J Surg* 1992, **164**:265-8.
42. Cornwell EE, Chang D, Velmahos G, Jindal A, Baker D, Phillips J, Bonar J, Campbell K: **Compliance with sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis.** *Am Surg* 2002, **68**:470-3.
43. Haddad FS, Kerry RM, McEwen JA, Appleton L, Garbuz DS, Masri BA, Duncan CP: **Unanticipated variations between expected and delivered pneumatic compression therapy after elective hip surgery: a possible source of variation in reported patient outcomes.** *J Arthroplasty* 2001, **16**:37-46.
44. Carlin AM, Tyburski JG, Wilson RF, Steffes C: **Prophylactic and therapeutic inferior vena cava filters to prevent pulmonary emboli in trauma patients.** *Arch Surg* 2002, **137**:521-7.
45. Khansarinia S, Dennis JW, Veldenz HC, Butcher JL, Hartland L: **Prophylactic Greenfield filter placement in selected high-risk trauma patients.** *J Vasc Surg* 1995, **22**:231-6.
46. Langan EM, Miller RS, Casey WJ, Carsten CG, Graham RM, Taylor SM: **Prophylactic inferior vena cava filters in trauma patients at high risk: follow-up examination and risk/benefit assessment.** *J Vasc Surg* 1999, **30**:484-88.
47. Rodriguez JL, Lopez JM, Proctor MC, Conley JL, Gerndt SJ, Marx MV, Taheri PA: **Early placement of prophylactic vena caval filters in injured patients at high risk for pulmonary embolism.** *J Trauma* 1996, **40**:797-804.
48. Rogers FB, Shackford SR, Ricci MA, Wilson JT, Parsons S: **Routine prophylactic vena cava filter insertion in severely injured trauma patients decreases the incidence of pulmonary embolism.** *J Am Coll Surg* 1995, **180**:641-7.
49. Rogers FB, Strindberg G, Shackford SR, Osler TM, Morris CS, Ricci MA, Najarian KE, D'Astino R, Pilcher DB: **Five-year follow-up of prophylactic vena cava filters in high-risk trauma patients.** *Arch Surg* 1998, **133**:406-12.
50. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral B, Huet Y, Simonneau G: **A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients**

- with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. *N Engl J Med* 1998, **338**:409-15.
51. Darcy MD, Smith TP, Hunter DW, Castraneda-Zuniga W, Lund G, Amplatz K: Short-term prophylaxis of pulmonary embolism by using a retrievable vena cava filter. *AJR Am J Roentgenol* 1986, **147**:836-8.
  52. Hoff WS, Hoey BA, Wainwright GA, Reed JF, Ball DS, Ringold M, Grossman MD: Early experience with retrievable inferior vena cava filters in high-risk trauma patients. *J Am Coll Surg* 2004, **199**:869-74.
  53. Offner PJ, Hawkes A, Madayag R, Seale F, Maines C: The role of temporary inferior vena cava filters in critically ill surgical patients. *Arch Surg* 2003, **138**:591-5.
  54. Allen TL, Carter JL, Morris BJ, Harker CP, Stevens MH: Retrievable vena cava filters in trauma patients for high-risk prophylaxis and prevention of pulmonary embolism. *Am J Surg* 2005, **189**:656-61.
  55. Rosenthal D, Wellons ED, Levitt AB, Shuler FW, O'Connor RE, Henderson VJ: Role of prophylactic temporary inferior vena cava filters placed at the ICU bedside under intravascular ultrasound guidance in patients with multiple trauma. *J Vasc Surg* 2004, **40**:958-64.
  56. Streiff MB: Vena caval filters: a comprehensive review. *Blood* 2000, **95**:3669-77.
  57. Messmer JM, Greenfield LJ: Greenfield caval filters: long-term radiographic follow-up study. *Radiology* 1985, **156**:613-8.
  58. Athanasoulis CA, Kaufman JA, Halpern EF, Waltman AC, Geller SC, Fan CM: Inferior vena caval filters: review of a 26-year single-center clinical experience. *Radiology* 2000, **216**:54-66.
  59. Greenfield LJ, Proctor MC, Michaels AJ, Taheri PA: Prophylactic vena caval filters in trauma: the rest of the story. *J Vasc Surg* 2000, **32**:490-7.
  60. Patton JH Jr, Fabian TC, Croce MA, Minard G, Pritchard FE, Kudsk KA: Prophylactic Greenfield filters: acute complications and long-term follow-up. *J Trauma* 1996, **41**:231-7.
  61. Poletti PA, Becker CD, Prina L, Rujis P, Bounameaux H, Didier D, Schneider PA, Terrier F: Long-term results of the Simon nitinol inferior vena cava filter. *Eur Radiol* 1998, **8**:289-94.
  62. Starok MS, Common AA: Follow-up after insertion of Bird's Nest inferior vena caval filters. *Can Assoc Radiol J* 1996, **47**:189-94.
  63. Greenfield LJ, Cho KJ, Tauscher JR: Limitations of percutaneous insertion of Greenfield filters. *J Cardiovasc Surg* 1990, **31**:344-50.
  64. Feezor RJ, Huber TS, Welborn MB, Schell SR: Duodenal perforation with an inferior vena cava filter: an unusual cause of abdominal pain. *J Vasc Surg* 2002, **35**:1010-2.
  65. Putterman D, Niman D, Cohen G: Aortic pseudoaneurysm after penetration by a Simon nitinol inferior vena cava filter. *J Vasc Interv Radiol* 2005, **16**:535-8.
  66. Goldman KA, Adelman MA: Retroperitoneal caval filter as a source of abdominal pain. *Cardiovasc Surg* 1994, **2**:85-7.
  67. Miller CL, Wechsler RJ: CT evaluation of Kimray-Greenfield filter complications. *Am J Roentgenol* 1986, **147**:45-50.
  68. Goldman HB, Hanna K, Dmochowski RR: Ureteral injury secondary to an inferior vena caval filter. *J Urol* 1996, **156**:1763.
  69. Dabbagh A, Chakfe N, Kretz JG, Cemri B, Nicolini P, Fuentes C, Mettauer B, Epailly E, Muster D, Eisenmann B: Late complication of a Greenfield filter associating caudal migration and perforation of the abdominal aorta by a ruptured strut. *J Vasc Surg* 1995, **22**:182-7.
  70. Kinney TB: Update on inferior vena cava filters. *J Vasc Interv Radiol* 2003, **14**:425-40.
  71. Binkert CA, Bansal A, Gates JD: Inferior vena cava filter removal after 317-day implantation. *J Vasc Interv Radiol* 2005, **16**:395-8.
  72. Asch MR: Initial experience in humans with a new retrievable inferior vena cava filter. *Radiology* 2002, **225**:835-44.
  73. Bovyn G, Gory P, Reynaud P, Ricco JB: The Tempofilter: a multicenter study of a new temporary caval filter implantable for up to six weeks. *Ann Vasc Surg* 1997, **11**:520-8.
  74. Millward SF, Bhargava A, Aquino J Jr, Peterson RA, Veinot JP, Bormanis J, Wells PS: Gunther Tulip filter: preliminary clinical experience with retrieval. *J Vasc Interv Radiol* 2000, **11**:75-82.
  75. Millward SF, Bormanis J, Burbridge BE, Markman SJ, Peterson RA: Preliminary clinical experience with the Gunther temporary inferior vena cava filter. *J Vasc Interv Radiol* 1994, **5**:863-8.
  76. Millward SF, Oliva VL, Bell SD, Valenti DA, Rasuli P, Asch M, Hadziomerovic A, Kachura JR: Gunther Tulip Retrievable Vena Cava Filter: results from the Registry of the Canadian Interventional Radiology Association. *J Vasc Interv Radiol* 2001, **12**:1053-8.
  77. Neuerburg JM, Gunther RW, Vorwerk D, Dondelinger RF, Jager H, Lackner KJ, Schild HH, Plant GR, Joffe FG, Schneider PA, Janssen JH: Results of a multicenter study of the retrievable Tulip Vena Cava Filter: early clinical experience. *Cardiovasc Intervent Radiol* 1997, **20**:10-6.
  78. Wicky S, Doenz F, Meuwly JY, Portier F, Schnyder P, Denys A: Clinical experience with retrievable Gunther Tulip vena cava filters. *J Endovasc Ther* 2003, **10**:994-1000.
  79. Kaufman JA, Kinney TB, Streiff MB, Sing RF, Proctor MC, Becker D, Cipolle M, Comerota AJ, Millward SF, Rogers FB, Sacks D, Venbrux AC: Guidelines for the use of retrievable and convertible vena cava filters: Report from the Society of Interventional Radiology multidisciplinary consensus conference. *Surg Obes Relat Dis* 2006, **2**:200-12.

doi:10.1186/1752-2897-4-1

**Cite this article as:** Datta et al.: Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature. *Journal of Trauma Management & Outcomes* 2010 **4**:1.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
http://www.biomedcentral.com/info/publishing\_adv.asp

